Novoteris is Dedicated to Stopping Microbe-induced Lung Damage in Cystic Fibrosis
Our mission is to find effective non-antibiotic antimicrobial therapies for people with serious respiratory infections or chronic airway colonization, to extend or improve the quality of their lives.
Thiolanox®
Novoteris is focused on developing inhaled nitric oxide gas formulations to address some of the most serious and lethal respiratory tract infections. Our scientists have spent two decades studying and developing nitric oxide for the treatment of drug resistance infections in diseases such as tuberculosis, cystic fibrosis, bronchiectasis, and chronic sinus disease.
Contact Us
If you’re intrigued by what you’ve read about Novoteris LLC and would like to learn more, please contact us by completing the contact form.